ISDA

Deposition Date 2016-03-07

Release Date 2016-05-04

Last Version Date 2024-03-20

Entry Detail

PDB ID:

5IMX

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.12 Å

R-Value Free:

0.25

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:ALK tyrosine kinase receptor
Gene (Uniprot):ALK
Chain IDs:A
Chain Length:327
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9UM73 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

CZ4

Primary Citation

Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Zhang, P, Dong, J, Zhong, B, Zhang, D, Yuan, H, Jin, C, Xu, X, Li, H, Zhou, Y, Liang, Z, Ji, M, Xu, T, Song, G, Zhang, L, Chen, G, Meng, X, Sun, D, Shih, J, Zhang, R, Hou, G, Wang, C, Jin, Y, Yang, Q.Show

Bioorg.Med.Chem.Lett. 26 1910 1918 (2016)

PMID: 26979157 DOI: 10.1016/j.bmcl.2016.03.017

Abstact

Anaplastic lymphoma kinase (ALK) is a highly attractive therapeutic target for the treatment of some non-small cell lung cancer patients. This Letter describes the further SAR exploration on the novel 3-sulfonylpyrazol-4-amino pyrimidine scaffold. This work identified a compound 53 with very good in vitro/in vivo efficacies, good DMPK properties together with better hERG tolerability and it is currently being profiled for the evaluation as a potential pre-clinical candidate.

Legend

Protein

Chemical

Disease

Primary Citation of related structures